EVAX Evaxion Biotech A/S

Nasdaq evaxion-biotech.com


$ 5.65 $ -0.24 (-4.07 %)    

Monday, 03-Nov-2025 12:06:34 EST
QQQ $ 632.67 $ -2.55 (-0.4 %)
DIA $ 473.98 $ -2.16 (-0.45 %)
SPY $ 683.51 $ -2.13 (-0.31 %)
TLT $ 89.52 $ -0.13 (-0.15 %)
GLD $ 368.80 $ 0.01 (0 %)
$ 5.75
$ 5.77
$ 5.53 x 100
$ 5.68 x 21
$ 5.61 - $ 5.88
$ 1.20 - $ 13.80
142,284
na
403.25M
$ 4.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evaxion-expands-rd-pipeline-with-addition-evx-04-ai-designed-precision-cancer-vaccine-candidate

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our...

 edward-jones-initiates-coverage-on-evaxion-with-buy-rating-announces-price-target-of-10

Edward Jones analyst Soumit Roy initiates coverage on Evaxion (NASDAQ:EVAX) with a Buy rating and announces Price Target of ...

 evaxion-as-appoints-helen-tayton-martin-ceo-effective-nov-24

Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powe...

 lake-street-maintains-buy-on-evaxion-raises-price-target-to-11

Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and raises the price target from $6 to $11.

 hc-wainwright--co-reiterates-buy-on-evaxion-maintains-16-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price t...

 evaxion-as-reports-two-year-phase-2-data-showing-results-for-its-personalized-cancer-vaccine-evx-01-in-advanced-melanoma-study-showed-a-75-objective-response-rate-with-4-of-16-patients-achieving-complete-responses-and-92-maintaining-durable-responses-at-24-months-with-no-relapses

Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ power...

 evaxion-will-present-comprehensive-phase-2-trial-data-for-its-lead-cancer-vaccine-evx-01-at-the-esmo-congress-2025-in-berlin-oct-1721-2025

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on ...

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outst...

 hc-wainwright--co-maintains-buy-on-evaxion-raises-price-target-to-16

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Evaxion (NASDAQ: EVAX) with a Buy and raises the price targ...

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

Core News & Articles

OPEN: 11% | Opendoor shares are trading higher after Jane Street Group disclosed in a 13G filing that it holds a 5.9% stake in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION